Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diammonium Glycyrrhizinate + Dexamethasone in Treatment-naive Primary ITP
NCT05023915Phase 2Active, not recruiting
- Sponsor
- Shandong University
- Start
- Aug 2021
- Primary completion
- Aug 2021
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of glycyrrhizin in immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoints: 14-day initial overall response to ITP treatments and 6-month sustained overall response to ITP treatments. Started Aug 2021; status: active, not recruiting.
02
Drugs
glycyrrhizin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05023915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023915.